News | June 01, 2009

Study Measures Femoral Access Site Complications among 18,165 Patients

June 1, 2009 - A new study shows about 2 percent of 18,165 patients undergoing cardiac catheterization had femoral vascular complications.

The study conducted by the Bad Berka Central Clinic, Department of Cardiology in Germany, appears in the June 12 issue of the International Journal of Cardiology (Volume 135, June 12, 2009, Issue 1, Pages 66-71).

The affected patients acquired femoral arterio-venous fistulas (AVF) and arterial pseudoaneurysms (PSA), for which patient- or procedure-related risk factors could be identified. Most of AVF and PSA could be managed conservatively or without any treatment, the overall mortality is low, researchers said.

The study was conducted because the incidence, risk factors and clinical outcome of femoral access complications are not well defined, although important for stratification and treatment.

A total of 18,165 consecutive patients undergoing cardiac catheterization were enrolled in the prospective registry. For the diagnosis of AVF and PSA a clinical examination was performed in every patient followed by a Duplex examination in case of clinical suspicion of AVF/PSA. The impact of the following risk factors was assessed: age, body mass index, puncture of left vs. right groin, gender, hypertension, sheath size, peripheral artery disease, coumadin therapy, glycoprotein IIb/IIIa-inhibitors, pretreatment with thrombolytics, and emergency procedures.

Within three years a total of 334 complications were found (1.8 percent). The incidence of AVF and PSA was 0.6 percent (n=107) and 1.2 percent (n=227), respectively. The following significant independent risk factors were identified: arterial hypertension (odds ratio [OR])=1.86, female gender (OR=1.65), and emergency procedures (OR=2.13). During follow-up (mean 48±10 months) only 11 percent of all AVF underwent operative repair due to symptoms. The study found PSA could be treated successfully either by manual compression, thrombin injection, or surgery. The overall mortality was 0.8 percent, the study found.

For more information: www.internationaljournalofcardiology.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now